Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

61. Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events

Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events 27898235 2017 06 07 2018 11 13 2326-5108 14 6 2016 Nov/Dec Health security Health Secur Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events. 419-423 Anthrax postexposure prophylaxis (PEP) was recommended to 42 people after a laboratory incident that involved potential aerosolization of Bacillus anthracis spores in 2 laboratories at the Centers for Disease Control (...) and Prevention in 2014. At least 31 (74%) individuals who initiated PEP did not complete either the recommended 60 days of antimicrobial therapy or the 3-dose vaccine regimen. Among the 29 that discontinued the antimicrobial component of PEP, most (38%) individuals discontinued PEP because of their low perceived risk of infection; 9 (31%) individuals discontinued prophylaxis due to PEP-related minor adverse events, and 10% cited both low risk and adverse events as their reason for discontinuation. Most minor

Health security2016 Full Text: Link to full Text with Trip Pro

62. US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014.

US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. Importance: The Patient Protection and Affordable Care Act of 2010 brought attention to adverse drug events in national patient safety efforts. Updated, detailed, nationally representative data describing adverse drug events can help focus these efforts. Objective: To describe the characteristics of emergency department (ED) visits for adverse drug events in the United States in 2013-2014 and describe changes in ED (...) visits for adverse drug events since 2005-2006. Design, Setting, and Participants: Active, nationally representative, public health surveillance in 58 EDs located in the United States and participating in the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project. Exposures: Drugs implicated in ED visits. Main Outcomes and Measures: National weighted estimates of ED visits and subsequent hospitalizations for adverse drug events. Results: Based on data from

JAMA2016

63. Reducing Adverse Drug Events: The Need to Rethink Outpatient Prescribing

Reducing Adverse Drug Events: The Need to Rethink Outpatient Prescribing 27893112 2016 12 13 2018 11 13 1538-3598 316 20 2016 Nov 22 JAMA JAMA Reducing Adverse Drug Events: The Need to Rethink Outpatient Prescribing. 2092-2093 10.1001/jama.2016.16392 Kessler Chad C Durham VA Medical Center, Durham, North Carolina. Ward Michael J MJ Vanderbilt University Medical Center, Nashville, Tennessee. McNaughton Candace D CD Vanderbilt University Medical Center, Nashville, Tennessee. eng K23 HL125670 HL (...) Engl J Med. 2012 Aug 2;367(5):391-3 22784039 MMWR Morb Mortal Wkly Rep. 2016 Jan 01;64(50-51):1378-82 26720857 Drug-Related Side Effects and Adverse Reactions Humans Medication Errors Outpatients 2016 11 29 6 0 2016 11 29 6 0 2016 12 15 6 0 ppublish 27893112 2585959 10.1001/jama.2016.16392 PMC5779096 NIHMS934127

JAMA2016 Full Text: Link to full Text with Trip Pro

65. Hyaluronic acid injection therapy for osteoarthritis of the knee: concordant efficacy and conflicting serious adverse events in two systematic reviews.

Hyaluronic acid injection therapy for osteoarthritis of the knee: concordant efficacy and conflicting serious adverse events in two systematic reviews. BACKGROUND: The prevalence of knee osteoarthritis (OA)/degenerative joint disease (DJD) is increasing in the USA. Systematic reviews of treatment efficacy and adverse events (AEs) of hyaluronic acid (HA) injections report conflicting evidence about the balance of benefits and harms. We review evidence on efficacy and AEs of intraarticular (...) functional outcomes: pooled analysis of ten placebo-controlled, blinded trials showed a standardized mean difference of -0.23 (95 % confidence interval (CI) -0.45 to -0.01) favoring HA at 6 months. Studies reported few serious adverse events (SAEs) and no significant differences in non-serious adverse events (NSAEs) (relative risk (RR) [95 % CI] 1.03 [0.93-1.15] or SAEs (RR [95 % CI] 1.39 [0.78-2.47]). A recent prior systematic review reported similar functional outcomes, but significant SAE risk

Systematic Reviews2016 Full Text: Link to full Text with Trip Pro

66. Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials Data

Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials Data 27751983 2018 11 13 2291-9694 4 4 2016 Oct 17 JMIR medical informatics JMIR Med Inform Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials Data. e30 Understanding adverse event patterns in clinical studies across populations is important for patient safety and protection in clinical trials as well as for developing appropriate drug therapies, procedures, and treatment (...) plans. The objective of our study was to conduct a data-driven population-based analysis to estimate the incidence, diversity, and association patterns of adverse events by age of the clinical trials patients and participants. Two aspects of adverse event patterns were measured: (1) the adverse event incidence rate in each of the patient age groups and (2) the diversity of adverse events defined as distinct types of adverse events categorized by organ system. Statistical analysis was done

JMIR medical informatics2016 Full Text: Link to full Text with Trip Pro

67. Gender differences in effects and adverse events of drugs

Gender differences in effects and adverse events of drugs Gender differences in effects and adverse events of drugs - Nasjonalt kunnskapssenter for helsetjenesten Main menu Menu The Knowledge Centre for the Health Services is part of the Norwegian Institute of Public Health since January 1, 2016. For new publications, please go to Search Rapport fra Folkehelseinstituttet - Systematisk litteratursøk med sortering Gender differences in effects and adverse events of drugs Published 18/08/2016 (...) Holte HH, Underland V, Straumann GH. Gender differences in effects and adverse events of drugs. Rapport fra Folkehelseinstituttet – 2016. ISBN 978-82-8082-740-1 Key messages The Norwegian Directorate of Health commissioned The Knowledge Centre in the Norwegian Institute of Public Health to do a systematic search for systematic reviews and sorting of any possibly relevant abstracts on gender differences in effects and adverse events of drugs. Methods We searched for published and ongoing systematic

The Norwegian Knowledge Centre for the Health Services2016

68. Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting

Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting 27453515 2016 08 17 2016 08 17 1879-1913 118 5 2016 Sep 01 The American journal of cardiology Am. J. Cardiol. Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients (...) and Cardiac Surgery (SYNTAX) score, the Anatomical and Clinical Syntax II Score and the Reduction of Atherothrombosis for Continued Health score. These 5 scores were investigated in patients with AF with coronary stenting with the aim of determining which was most predictive for stroke/thromboembolic (TE) events, nonlethal coronary events, all-cause mortality, and major adverse cardiac events (MACE). Among 845 patients with AF with coronary stenting seen from 2000 to 2014, 440 (52%) were admitted

EvidenceUpdates2016

69. Diagnostic Accuracy of High-Sensitivity Cardiac Troponin T at Presentation Combined With History and ECG for Ruling Out Major Adverse Cardiac Events

Diagnostic Accuracy of High-Sensitivity Cardiac Troponin T at Presentation Combined With History and ECG for Ruling Out Major Adverse Cardiac Events 27471140 2016 07 29 2016 11 29 1097-6760 68 6 2016 Dec Annals of emergency medicine Ann Emerg Med Diagnostic Accuracy of High-Sensitivity Cardiac Troponin T at Presentation Combined With History and ECG for Ruling Out Major Adverse Cardiac Events. 649-658.e3 S0196-0644(16)30263-3 10.1016/j.annemergmed.2016.06.008 We evaluate the diagnostic accuracy (...) of a high-sensitivity cardiac troponin T (hs-cTnT) level less than 5 ng/L or less than or equal to 14 ng/L at emergency department (ED) presentation, combined with the emergency physician's assessment of history and ECG, for ruling out major adverse cardiac events within 30 days. This prospective observational study enrolled consecutive ED chest pain patients. Emergency physicians' assessments of patient history and ECG were collected. The primary outcome was 30-day major adverse cardiac events, defined

EvidenceUpdates2016

70. Induction of labour with retrievable prostaglandin vaginal inserts: outcomes following retrieval due to an intrapartum adverse event

Induction of labour with retrievable prostaglandin vaginal inserts: outcomes following retrieval due to an intrapartum adverse event 27307397 2016 06 27 2017 04 26 1471-0528 124 5 2017 Apr BJOG : an international journal of obstetrics and gynaecology BJOG Induction of labour with retrievable prostaglandin vaginal inserts: outcomes following retrieval due to an intrapartum adverse event. 796-803 10.1111/1471-0528.14147 To assess adverse event (AE) resolution, delivery mode and neonatal outcomes (...) time to delivery for either prostaglandin insert. Induction with prostaglandin vaginal inserts: outcomes following retrieval due to intrapartum adverse event. © 2016 Ferring Pharmaceuticals. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists. Rugarn O O Ferring Pharmaceuticals, Copenhagen, Denmark. Tipping D D Tipping Consulting LLC, Green Lane, PA, USA. Powers B B Independent Consultant

EvidenceUpdates2016

71. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.

Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. 27438319 2016 07 21 2017 02 03 2380-6591 1 4 2016 Jul 01 JAMA cardiology JAMA Cardiol Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. 425-32 10.1001/jamacardio.2016.1017 In the PEGASUS-TIMI 54 trial, treatment with ticagrelor reduced (...) , respectively, discontinued treatment (P < .001). Discontinuation of treatment due to an adverse event occurred in 19%, 16%, and 9% of patients, respectively (P < .001). The most frequent adverse events leading to discontinuation of treatment were bleeding (with Kaplan-Meier event rates of 7.8%, 6.2%, and 1.5% of patients, respectively; P < .001) and dyspnea (6.5%, 4.6%, and 0.8% of patients, respectively; P < .001). Eighty-six percent of bleeding events that led to the discontinuation of treatment

JAMA cardiology2016

72. Seasonal and Geographic Variation in Adverse Event Reporting

Seasonal and Geographic Variation in Adverse Event Reporting 27747826 2018 11 13 2199-1154 3 3 2016 Sep Drugs - real world outcomes Drugs Real World Outcomes Seasonal and Geographic Variation in Adverse Event Reporting. 297-306 Many illnesses demonstrate seasonal and geographic variations. Pharmacovigilance is unique among public health surveillance systems in terms of the clinical diversity of the events under surveillance. Since many pharmacovigilance signal detection methodologies are geared (...) towards looking for increased frequency of spontaneous adverse drug event (ADE) reporting over variable time frames, seasonality of ADEs may have implications for signal detection. The aim of this study was to investigate whether a set of illnesses that might be expected to display seasonality in general, did so when spontaneously reported as ADEs. We performed our analysis with the publically available US FDA Adverse Event Reporting System (FAERS) data. We selected a convenience sample of events

Drugs - real world outcomes2016 Full Text: Link to full Text with Trip Pro

73. Usefulness of the Myocardial Infarction and Cardiac Arrest Calculator as a Discriminator of Adverse Cardiac Events After Elective Hip and Knee Surgery

Usefulness of the Myocardial Infarction and Cardiac Arrest Calculator as a Discriminator of Adverse Cardiac Events After Elective Hip and Knee Surgery 27131613 2016 05 30 2017 05 02 2017 05 02 1879-1913 117 12 2016 Jun 15 The American journal of cardiology Am. J. Cardiol. Usefulness of the Myocardial Infarction and Cardiac Arrest Calculator as a Discriminator of Adverse Cardiac Events After Elective Hip and Knee Surgery. 1992-5 10.1016/j.amjcard.2016.03.050 S0002-9149(16)30437-4 The 2014 (...) accurately discriminate adverse cardiac events in a cohort of adult patients undergoing elective orthopedic surgery. We retrospectively reviewed 1,098 consecutive, elective orthopedic surgeries performed at Hershey Medical Center from January 1, 2013, to December 31, 2014. Adverse cardiac events were defined as myocardial infarction or cardiac arrest within 30 days of surgery. The mean estimated risk for adverse cardiac events using the NSQIP MICA risk calculator was 0.54%, which was not significantly

EvidenceUpdates2016

74. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. 26954408 2016 03 09 2016 03 14 2016 10 17 1538-3598 315 10 2016 Mar 08 JAMA JAMA Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. 990-1004 10.1001/jama.2016.1558 Few cardiovascular outcomes trials have been conducted (...) for obesity treatments. Withdrawal of 2 marketed drugs has resulted in controversy about the cardiovascular safety of obesity agents. To determine whether the combination of naltrexone and bupropion increases major adverse cardiovascular events (MACE, defined as cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction) compared with placebo in overweight and obese patients. Randomized, multicenter, placebo-controlled, double-blind noninferiority trial enrolling 8910 overweight or obese

JAMA2016

75. Comparison of the Global Registry of Acute Coronary Events Risk Score Versus the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse outcomes With Early Implementation of the ACC/AHA Guidelines Risk Score to Predict In-Hospital Mort

Comparison of the Global Registry of Acute Coronary Events Risk Score Versus the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse outcomes With Early Implementation of the ACC/AHA Guidelines Risk Score to Predict In-Hospital Mort 26857164 2016 03 19 2016 07 29 2016 03 19 1879-1913 117 7 2016 Apr 01 The American journal of cardiology Am. J. Cardiol. Comparison of the Global Registry of Acute Coronary Events Risk Score Versus the Can Rapid Risk Stratification of Unstable (...) Angina Patients Suppress Adverse outcomes With Early Implementation of the ACC/AHA Guidelines Risk Score to Predict In-Hospital Mortality and Major Bleeding in Acute Coronary Syndromes. 1047-54 10.1016/j.amjcard.2015.12.048 S0002-9149(16)30003-0 Risk assessment plays a major role in the management of acute coronary syndrome. The aim was to compare the performance of the Global Registry of Acute Coronary Events (GRACE) and the Can Rapid risk stratification of Unstable angina patients Suppress Adverse

EvidenceUpdates2016

76. Predictive Validity of the Beers and Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse Drug Events, Hospitalizations, and Emergency Department Visits in the United States

Predictive Validity of the Beers and Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse Drug Events, Hospitalizations, and Emergency Department Visits in the United States 26782849 2016 01 19 2016 05 24 2017 02 24 1532-5415 64 1 2016 Jan Journal of the American Geriatrics Society J Am Geriatr Soc Predictive Validity of the Beers and Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse (...) Drug Events, Hospitalizations, and Emergency Department Visits in the United States. 22-30 10.1111/jgs.13884 To compare the predictive validity of the 2003 Beers, 2012 American Geriatrics Society (AGS) Beers, and Screening Tool of Older Persons' potentially inappropriate Prescriptions (STOPP) criteria. Retrospective cohort. Managed care administrative claims data from 2006 to 2009. Commercially insured persons aged 65 and older in the United States (N=174,275). Association between adverse drug

EvidenceUpdates2016

77. Systematic review with meta analysis: Low to moderate quality evidence demonstrates the potential benefits and adverse events of cannabinoids for certain medical indications

Systematic review with meta analysis: Low to moderate quality evidence demonstrates the potential benefits and adverse events of cannabinoids for certain medical indications Low to moderate quality evidence demonstrates the potential benefits and adverse events of cannabinoids for certain medical indications | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low to moderate quality evidence demonstrates the potential benefits and adverse events of cannabinoids for certain medical indications Article Text Therapeutics/Prevention Systematic review with meta

Evidence-Based Medicine (Requires free registration)2016

78. Observational study: Emergency department visits and hospitalisations for adverse events related to dietary supplements are common

Observational study: Emergency department visits and hospitalisations for adverse events related to dietary supplements are common Emergency department visits and hospitalisations for adverse events related to dietary supplements are common | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Emergency department visits and hospitalisations for adverse events related to dietary supplements are common Article Text Aetiology/Harm Observational study Emergency department visits and hospitalisations for adverse events related to dietary supplements

Evidence-Based Medicine (Requires free registration)2016

79. Disclosure and Discussion of Adverse Events

Disclosure and Discussion of Adverse Events Disclosure and Discussion of Adverse Events - ACOG Menu ▼ Disclosure and Discussion of Adverse Events Page Navigation ▼ Number 681, December 2016 (Replaces Committee Opinion No. 520, March 2012) Committee on Patient Safety and Quality Improvement This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Patient Safety and Quality Improvement in collaboration with committee member Edward P. Denious (...) , MD. This document reflects emerging concepts on patient safety and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Disclosure and Discussion of Adverse Events ABSTRACT: Adverse outcomes, preventable or otherwise, are a reality of medical care. Most importantly, adverse events affect patients, but they also affect health care practitioners. Disclosing information about adverse events has benefits

American College of Obstetricians and Gynecologists2016

80. Adverse events in oncology patients with reduced platelet counts and oncurrent anemia

Adverse events in oncology patients with reduced platelet counts and oncurrent anemia Adverse events in oncology patients with reduced platelet counts and oncurrent anemia Adverse events in oncology patients with reduced platelet counts and oncurrent anemia Mitchell MD, Wagner J, Wong,TC, Mull N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Mitchell MD, Wagner J, Wong,TC, Mull N. Adverse events in oncology patients with reduced platelet counts and oncurrent anemia. Philadelphia: Center for Evidence-based Practice (CEP). 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anemia; Humans; Leukopenia; Medical Oncology; Platelet Count; Thrombocytopenia Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence

Health Technology Assessment (HTA) Database.2016